Which Subgroup of Rheumatoid Arthritis Patients Benefits Most From Swichting to Rituximab Versus Alternative Anti-TNF Agenst After Previous Failure To Anit-TNF Agent?

Finckh, A; Ciurea, A; Burlhart, L; Möller, B; Walker, UA; Courvoisier, D; Kyburz, D; Dudler, J; Gabay, C (2009). Which Subgroup of Rheumatoid Arthritis Patients Benefits Most From Swichting to Rituximab Versus Alternative Anti-TNF Agenst After Previous Failure To Anit-TNF Agent? Annals of the rheumatic diseases, 69(2), pp. 387-393. London: BMJ Publishing Group 10.1136/ard.2008.105064

Full text not available from this repository.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology and Immunology
UniBE Contributor:	Möller, Burkhard
ISSN:	0003-4967
Publisher:	BMJ Publishing Group
Language:	English
Submitter:	Factscience Import
Date Deposited:	04 Oct 2013 15:11
Last Modified:	05 Dec 2022 14:22
Publisher DOI:	10.1136/ard.2008.105064
PubMed ID:	19416802
Web of Science ID:	000274047300014
URI:	https://boris.unibe.ch/id/eprint/31441 (FactScience: 195964)